Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine: relation to vascular effects - PubMed (original) (raw)
Affiliations
- PMID: 9167186
Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine: relation to vascular effects
B C Baguley et al. Oncol Res. 1997.
Abstract
A number of antitumor agents are known to cause selective reduction in tumor blood flow, leading in some cases to tumor necrosis and growth delay. These agents include flavone acetic acid (FAA), an antitumor agent with high experimental but no clinical antitumor activity, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a highly active analogue of FAA, endotoxin, vinblastine, and colchicine. We find here that plasma concentrations of serotonin (5-hydroxytryptamine) and its metabolite 5-hydroxyindole acetic acid (5-HIAA) are increased following administration of these agents. Mice were injected with each at the maximum tolerated dose and, at various times later, blood samples were taken, cells and platelets removed by centrifugation, and serotonin and 5-HIAA concentrations were measured by high performance liquid chromatography. FAA and DMXAA induced six- and sevenfold increases in serotonin and 5-HIAA, respectively, with maximal levels 4 h after drug administration. 8-Methylxanthenone-4-acetic acid, an inactive analogue of DMXAA, failed to increase serotonin and caused only a small increase in 5-HIAA. Endotoxin, vinblastine, and colchicine each caused increases in serotonin and 5-HIAA between 2 and 6 h after drug administration. The mitotic poison paclitaxel, despite inducing growth delays of Colon 38 tumors, did not induce tumor necrosis and caused no increase in serotonin or 5-HIAA up to 6 h. The effect of the presence of subcutaneous Colon 38 tumors was tested and found not to affect the induction of increases in serotonin and 5-HIAA by DMXAA and colchicine. We suggest that the increases in plasma serotonin and its metabolite are a result of drug-induced vascular effects in host tissues, and that measurement of these compounds provides a potential means of monitoring drugs exerting vascular effects.
Similar articles
- Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid.
Cao Z, Joseph WR, Browne WL, Mountjoy KG, Palmer BD, Baguley BC, Ching LM. Cao Z, et al. Br J Cancer. 1999 May;80(5-6):716-23. doi: 10.1038/sj.bjc.6690415. Br J Cancer. 1999. PMID: 10360649 Free PMC article. - Small-molecule cytokine inducers causing tumor necrosis.
Baguley BC. Baguley BC. Curr Opin Investig Drugs. 2001 Jul;2(7):967-75. Curr Opin Investig Drugs. 2001. PMID: 11757800 Review. - 5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy.
Zhou S, Kestell P, Baguley BC, Paxton JW. Zhou S, et al. Invest New Drugs. 2002 Aug;20(3):281-95. doi: 10.1023/a:1016215015530. Invest New Drugs. 2002. PMID: 12201491 Review.
Cited by
- Carboxyxanthones: Bioactive Agents and Molecular Scaffold for Synthesis of Analogues and Derivatives.
Ribeiro J, Veloso C, Fernandes C, Tiritan ME, Pinto MMM. Ribeiro J, et al. Molecules. 2019 Jan 5;24(1):180. doi: 10.3390/molecules24010180. Molecules. 2019. PMID: 30621303 Free PMC article. Review. - Preliminary Evidence That High-Dose Vitamin C has a Vascular Disrupting Action in Mice.
Baguley BC, Ding Q, Richardson E. Baguley BC, et al. Front Oncol. 2014 Nov 5;4:310. doi: 10.3389/fonc.2014.00310. eCollection 2014. Front Oncol. 2014. PMID: 25414833 Free PMC article. - The influence of the combined treatment with Vadimezan (ASA404) and taxol on the growth of U251 glioblastoma xenografts.
Milanović D, Braun F, Weber W, Grosu AL, Behe M, Niedermann G. Milanović D, et al. BMC Cancer. 2012 Jun 13;12:242. doi: 10.1186/1471-2407-12-242. BMC Cancer. 2012. PMID: 22695475 Free PMC article. - Cardiovascular toxicity profiles of vascular-disrupting agents.
Subbiah IM, Lenihan DJ, Tsimberidou AM. Subbiah IM, et al. Oncologist. 2011;16(8):1120-30. doi: 10.1634/theoncologist.2010-0432. Epub 2011 Jul 8. Oncologist. 2011. PMID: 21742963 Free PMC article. - Temporal aspects of the action of ASA404 (vadimezan; DMXAA).
Baguley BC, Siemann DW. Baguley BC, et al. Expert Opin Investig Drugs. 2010 Nov;19(11):1413-25. doi: 10.1517/13543784.2010.529128. Expert Opin Investig Drugs. 2010. PMID: 20964495 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous